person · Reporting owner
Cvijic Christine Mikail
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.NGNE · Entity 5160 | Director · President and CFO | July 06, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date July 06, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,040 |
Last balance in matching sequence
After 2026-07-07 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-06 · Sale · Disposed 600 · Balance 88,240 F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse. Row 2 · 2026-07-07 · Sale · Disposed 4,200 · Balance 84,040 F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.
F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 8, 2026 01:08 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 4,200 | $36.13 | $151,762.80 |
DisclosureSEC source: 0001543663-26-000017 · wk-form4_1783472909.xml · nonDerivative · entry 2 Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,040 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 01:08 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 600 | $36.02 | $21,612.60 |
DisclosureSEC source: 0001543663-26-000017 · wk-form4_1783472909.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,240 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 22:42 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 1,530 | $35.23 | $53,897.31 |
DisclosureSEC source: 0001543663-26-000015 · wk-form4_1783032175.xml · nonDerivative · entry 3 Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,840 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.255, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 22:42 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 2,531 | $34.58 | $87,519.45 |
DisclosureSEC source: 0001543663-26-000015 · wk-form4_1783032175.xml · nonDerivative · entry 2 Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,370 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $34.99, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:42 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 739 | $34.06 | $25,169.60 |
DisclosureSEC source: 0001543663-26-000015 · wk-form4_1783032175.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,901 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.005 to $34.095, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| May 06, 2026 Filed May 8, 2026 15:51 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 4,800 | $32.44 | $155,691.84 |
DisclosureSEC source: 0001543663-26-000013 · wk-form4_1778255465.xml · nonDerivative · entry 2 Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,640 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.695, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| May 06, 2026 Filed May 8, 2026 15:51 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 4,800 | $30.07 | $144,351.36 |
DisclosureSEC source: 0001543663-26-000013 · wk-form4_1778255465.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,440 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.31, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 21:38 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 2,558 | $21.62 | $55,315.98 |
DisclosureSEC source: 0001543663-26-000011 · wk-form4_1774905421.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,240 F1 · kind: On March 26, 2026, a Restricted Stock Unit ("RSU") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.10 to $21.91, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 22:01 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 263 | $22.02 | $5,791.13 |
DisclosureSEC source: 0001543663-26-000007 · wk-form4_1773784859.xml · nonDerivative · entry 3 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,798 F1 · kind: On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.075, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 22:01 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 1,395 | $21.25 | $29,636.91 |
DisclosureSEC source: 0001543663-26-000007 · wk-form4_1773784859.xml · nonDerivative · entry 2 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,061 F1 · kind: On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 22:01 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 2,387 | $20.42 | $48,748.27 |
DisclosureSEC source: 0001543663-26-000007 · wk-form4_1773784859.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,456 F1 · kind: On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.92 to $20.87, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 22:03 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 4,800 | $25.11 | $120,526.08 |
DisclosureSEC source: 0001543663-26-000005 · wk-form4_1772575431.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,843 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.325. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:49 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 131,900 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0001543663-26-000002 · wk-form4_1771976938.xml · derivative · entry 2 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,900 Underlying: Common Stock · 131,900 shares Expires 2036-02-20 F3 · derivative.exercise_date: This option represents the right to purchase 131,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:49 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001543663-26-000002 · wk-form4_1771976938.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,643 F1 · shares: Consist of 22,000 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. F2 · balance_after: Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 24,000 are held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| March 26, 2025 Filed Mar 29, 2025 01:29 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantEmployee Stock Option (Right to buy) · Derivative | 122,000 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0001404644-25-000023 · wk-form4_1743211773.xml · derivative · entry 2 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,000 Underlying: Common Stock · 122,000 shares Expires 2035-03-26 F3 · derivative.exercise_date: This option represents the right to purchase 122,000 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the date of grant with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. Read SEC document |
| March 26, 2025 Filed Mar 29, 2025 01:29 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantCommon Stock | 20,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001404644-25-000023 · wk-form4_1743211773.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,643 F1 · shares: Consist of 20,300 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. F2 · ownership.direct: Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 21:14 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 4,501 | $16.94 | $76,246.94 |
DisclosureSEC source: 0001404644-25-000007 · wk-form4_1742246088.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,343 F1 · kind: On March 12, 2024, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sale reported on this Form 4 relates exclusively to this mandatory sale upon vesting of the RSU. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.38 to $17.21, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.direct: Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 02:29 UTC | Neurogene Inc. NGNE · Entity 5160 | PurchaseCommon Stock | 24,000 | $20.48 | $491,400.00 |
DisclosureSEC source: 0001404644-24-000113 · wk-form4_1732588163.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,844 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.33 to $20.92, inclusive. The reporting person undertakes to provide to Neurogene Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 00:53 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantEmployee Stock Option (Right to buy) · Derivative | 53,900 | $0.00 Strike: $36.06 | $0.00 |
DisclosureSEC source: 0001404644-24-000008 · wk-form4_1710463991.xml · derivative · entry 2 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,900 Underlying: Common Stock · 53,900 shares Expires 2034-03-13 F1 · derivative.exercise_date: The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 00:53 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantCommon Stock | 31,903 | $0.00 | $0.00 |
DisclosureSEC source: 0001404644-24-000008 · wk-form4_1710463991.xml · nonDerivative · entry 1 Cvijic Christine Mikail · CIK 0001543663 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,844 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.